Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant

Abstract The huge worldwide demand for vaccines targeting SARS-CoV-2 has necessitated the continued development of novel improved formulations capable of reducing the burden of the COVID-19 pandemic. Herein, we evaluated novel protein subunit vaccine formulations containing a resistin-trimerized spi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bassel Akache, Tyler M. Renner, Anh Tran, Lise Deschatelets, Renu Dudani, Blair A. Harrison, Diana Duque, Julie Haukenfrers, Martin A. Rossotti, Francis Gaudreault, Usha D. Hemraz, Edmond Lam, Sophie Régnier, Wangxue Chen, Christian Gervais, Matthew Stuible, Lakshmi Krishnan, Yves Durocher, Michael J. McCluskie
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/9618e29b6e8e4f74b75065bea762626c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9618e29b6e8e4f74b75065bea762626c
record_format	dspace
spelling	oai:doaj.org-article:9618e29b6e8e4f74b75065bea762626c2021-11-14T12:18:38ZImmunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant10.1038/s41598-021-01363-72045-2322https://doaj.org/article/9618e29b6e8e4f74b75065bea762626c2021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-01363-7https://doaj.org/toc/2045-2322Abstract The huge worldwide demand for vaccines targeting SARS-CoV-2 has necessitated the continued development of novel improved formulations capable of reducing the burden of the COVID-19 pandemic. Herein, we evaluated novel protein subunit vaccine formulations containing a resistin-trimerized spike antigen, SmT1. When combined with sulfated lactosyl archaeol (SLA) archaeosome adjuvant, formulations induced robust antigen-specific humoral and cellular immune responses in mice. Antibodies had strong neutralizing activity, preventing viral spike binding and viral infection. In addition, the formulations were highly efficacious in a hamster challenge model reducing viral load and body weight loss even after a single vaccination. The antigen-specific antibodies generated by our vaccine formulations had stronger neutralizing activity than human convalescent plasma, neutralizing the spike proteins of the B.1.1.7 and B.1.351 variants of concern. As such, our SmT1 antigen along with SLA archaeosome adjuvant comprise a promising platform for the development of efficacious protein subunit vaccine formulations for SARS-CoV-2.Bassel AkacheTyler M. RennerAnh TranLise DeschateletsRenu DudaniBlair A. HarrisonDiana DuqueJulie HaukenfrersMartin A. RossottiFrancis GaudreaultUsha D. HemrazEdmond LamSophie RégnierWangxue ChenChristian GervaisMatthew StuibleLakshmi KrishnanYves DurocherMichael J. McCluskieNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-17 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Bassel Akache Tyler M. Renner Anh Tran Lise Deschatelets Renu Dudani Blair A. Harrison Diana Duque Julie Haukenfrers Martin A. Rossotti Francis Gaudreault Usha D. Hemraz Edmond Lam Sophie Régnier Wangxue Chen Christian Gervais Matthew Stuible Lakshmi Krishnan Yves Durocher Michael J. McCluskie Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant
description	Abstract The huge worldwide demand for vaccines targeting SARS-CoV-2 has necessitated the continued development of novel improved formulations capable of reducing the burden of the COVID-19 pandemic. Herein, we evaluated novel protein subunit vaccine formulations containing a resistin-trimerized spike antigen, SmT1. When combined with sulfated lactosyl archaeol (SLA) archaeosome adjuvant, formulations induced robust antigen-specific humoral and cellular immune responses in mice. Antibodies had strong neutralizing activity, preventing viral spike binding and viral infection. In addition, the formulations were highly efficacious in a hamster challenge model reducing viral load and body weight loss even after a single vaccination. The antigen-specific antibodies generated by our vaccine formulations had stronger neutralizing activity than human convalescent plasma, neutralizing the spike proteins of the B.1.1.7 and B.1.351 variants of concern. As such, our SmT1 antigen along with SLA archaeosome adjuvant comprise a promising platform for the development of efficacious protein subunit vaccine formulations for SARS-CoV-2.
format	article
author	Bassel Akache Tyler M. Renner Anh Tran Lise Deschatelets Renu Dudani Blair A. Harrison Diana Duque Julie Haukenfrers Martin A. Rossotti Francis Gaudreault Usha D. Hemraz Edmond Lam Sophie Régnier Wangxue Chen Christian Gervais Matthew Stuible Lakshmi Krishnan Yves Durocher Michael J. McCluskie
author_facet	Bassel Akache Tyler M. Renner Anh Tran Lise Deschatelets Renu Dudani Blair A. Harrison Diana Duque Julie Haukenfrers Martin A. Rossotti Francis Gaudreault Usha D. Hemraz Edmond Lam Sophie Régnier Wangxue Chen Christian Gervais Matthew Stuible Lakshmi Krishnan Yves Durocher Michael J. McCluskie
author_sort	Bassel Akache
title	Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant
title_short	Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant
title_full	Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant
title_fullStr	Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant
title_full_unstemmed	Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant
title_sort	immunogenic and efficacious sars-cov-2 vaccine based on resistin-trimerized spike antigen smt1 and sla archaeosome adjuvant
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/9618e29b6e8e4f74b75065bea762626c
work_keys_str_mv	AT basselakache immunogenicandefficacioussarscov2vaccinebasedonresistintrimerizedspikeantigensmt1andslaarchaeosomeadjuvant AT tylermrenner immunogenicandefficacioussarscov2vaccinebasedonresistintrimerizedspikeantigensmt1andslaarchaeosomeadjuvant AT anhtran immunogenicandefficacioussarscov2vaccinebasedonresistintrimerizedspikeantigensmt1andslaarchaeosomeadjuvant AT lisedeschatelets immunogenicandefficacioussarscov2vaccinebasedonresistintrimerizedspikeantigensmt1andslaarchaeosomeadjuvant AT renududani immunogenicandefficacioussarscov2vaccinebasedonresistintrimerizedspikeantigensmt1andslaarchaeosomeadjuvant AT blairaharrison immunogenicandefficacioussarscov2vaccinebasedonresistintrimerizedspikeantigensmt1andslaarchaeosomeadjuvant AT dianaduque immunogenicandefficacioussarscov2vaccinebasedonresistintrimerizedspikeantigensmt1andslaarchaeosomeadjuvant AT juliehaukenfrers immunogenicandefficacioussarscov2vaccinebasedonresistintrimerizedspikeantigensmt1andslaarchaeosomeadjuvant AT martinarossotti immunogenicandefficacioussarscov2vaccinebasedonresistintrimerizedspikeantigensmt1andslaarchaeosomeadjuvant AT francisgaudreault immunogenicandefficacioussarscov2vaccinebasedonresistintrimerizedspikeantigensmt1andslaarchaeosomeadjuvant AT ushadhemraz immunogenicandefficacioussarscov2vaccinebasedonresistintrimerizedspikeantigensmt1andslaarchaeosomeadjuvant AT edmondlam immunogenicandefficacioussarscov2vaccinebasedonresistintrimerizedspikeantigensmt1andslaarchaeosomeadjuvant AT sophieregnier immunogenicandefficacioussarscov2vaccinebasedonresistintrimerizedspikeantigensmt1andslaarchaeosomeadjuvant AT wangxuechen immunogenicandefficacioussarscov2vaccinebasedonresistintrimerizedspikeantigensmt1andslaarchaeosomeadjuvant AT christiangervais immunogenicandefficacioussarscov2vaccinebasedonresistintrimerizedspikeantigensmt1andslaarchaeosomeadjuvant AT matthewstuible immunogenicandefficacioussarscov2vaccinebasedonresistintrimerizedspikeantigensmt1andslaarchaeosomeadjuvant AT lakshmikrishnan immunogenicandefficacioussarscov2vaccinebasedonresistintrimerizedspikeantigensmt1andslaarchaeosomeadjuvant AT yvesdurocher immunogenicandefficacioussarscov2vaccinebasedonresistintrimerizedspikeantigensmt1andslaarchaeosomeadjuvant AT michaeljmccluskie immunogenicandefficacioussarscov2vaccinebasedonresistintrimerizedspikeantigensmt1andslaarchaeosomeadjuvant
_version_	1718429302661316608

Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant

Ejemplares similares